FDA Grants Fast Track Designation to Inozyme Pharma’s INZ-701 for the Treatment of Patients with ABCC6 Deficiency

The Fast Track designation for INZ-701 is based on preclinical pharmacology and preliminary safety and efficacy data from an ongoing Phase I/II study of INZ-701 in adults with ABCC6 deficiency.